Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets OMIDRIA for use during cataract surgery or intraocular lens replacement. The company's clinical products include OMS721 that is in Phase III clinical trials for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trials for the treatment of thrombotic microangiopathies, IgA nephropathy, and other renal diseases. Its clinical programs also comprise OMS824, which is in Phase II clinical trials for the treatment of schizophrenia and Huntington's diseases; OMS405 that is in Phase II clinical trials for the treatment of opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trials for use during urological procedures. The company's preclinical programs include OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 to control surgical and traumatic bleeding; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Its preclinical programs also comprise GPR17 for the treatment of demyelinating disorders; GPR101 for appetite and eating disorders; GPR151 for the treatment of neuropathic pain and cognition; GPR161 for triple-negative breast cancer treatment; GPR174 for dysfunction of regulatory T-cell modulation; GPR183 for the treatment of osteoporosis and EBV-related diseases; and GPCR and Antibody Platform for CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trials for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
The number of shares of our common stock to be outstanding immediately after this offering, as reported above, is based on 39,277,231 shares outstanding as of June 30, 2016, and excludes as of that date: • 9,501,818 shares of common stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $8.60 per share; • 100,602 shares of common stock issuable upon the exercise of outstanding warrants with an exercise price of $9.94 per share; and • 1,896,593 shares of common stock available for future grants under our 2008 Equity Incentive Plan. Looks like some exercising going on following the last form 42. 3 of those in a row, didn't read them but they want cash for something fast imo. https://www.sec.gov/Archives/edgar/data/1285819/000119312516681910/d237085d424b5.htm
It goes some news! Omeros Announces Positive Data from OMS721 Phase 2 Clinical Trial in Renal Diseases
Had I played this, it would have been only for the bounce. I have a couple bio's that could use a bounce like this puppy!!
This is an impressive bounce, I guess nobody knew it was coming judging by the selling we saw on Friday! Those longs that sold are kicking themselves now, but you cant blame them, this thing was in a dive!
No doubt. Stop loss exists for a reason though I have a pretty high degree of tolerance if I'm really long on something. This was near $12. No way I would have ridden it under $10. As a possible dead cat bounce I was expecting this to go lower first. News saved it, for the moment.
Its situations like this that make people hate stop losses! You stick to your rules, you get out because it dropped, but then you come back Monday only to see everything completely reverse! AAArrrgghhh lol
Classic dead cat bounce here imo. Only P2 news so they'll likely have milestone payments which will dilute it. They're out of the money on all their warrants.
Omeros Announces Completion of Initial Funding under $125 Million Credit Facility http://finance.yahoo.com/news/omeros-announces-completion-initial-funding-110000886.html
Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative Pathway http://www.businesswire.com/news/ho...gle-Dose-Omeros’-Lead-MASP-3-Inhibitor-OMS906
Analyst Upgrade/Downgrade Update Brokerage firm: Wedbush Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Outperform Previous Price Target: $56 Current Price Target: $47
Oh boy, that was amazing! Im not so sure about tomorrows action to the upside, Ill watch for a potential short.
